vs
Side-by-side financial comparison of Bitcoin Depot Inc. (BTM) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Bitcoin Depot Inc. is the larger business by last-quarter revenue ($162.5M vs $103.7M, roughly 1.6× Twist Bioscience Corp). Bitcoin Depot Inc. runs the higher net margin — 3.4% vs -29.4%, a 32.8% gap on every dollar of revenue. On growth, Bitcoin Depot Inc. posted the faster year-over-year revenue change (20.1% vs 16.9%). Bitcoin Depot Inc. produced more free cash flow last quarter ($2.5M vs $-34.8M).
Bitcoin Depot Inc. is one of the largest cryptocurrency ATM operators across North America. It provides retail consumers with accessible in-person kiosks to buy and sell Bitcoin and other leading digital assets, alongside online crypto purchase services via bank transfer. Its self-service kiosks are located in high-traffic retail spaces including grocery stores, gas stations and convenience stores.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
BTM vs TWST — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $162.5M | $103.7M |
| Net Profit | $5.5M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 7.3% | -31.7% |
| Net Margin | 3.4% | -29.4% |
| Revenue YoY | 20.1% | 16.9% |
| Net Profit YoY | 690.4% | 3.4% |
| EPS (diluted) | $0.08 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $103.7M | ||
| Q3 25 | $162.5M | — | ||
| Q2 25 | $172.1M | — | ||
| Q1 25 | $164.2M | — | ||
| Q3 24 | $135.3M | — | ||
| Q2 24 | $163.1M | — | ||
| Q1 24 | $138.5M | — | ||
| Q4 23 | $148.4M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $5.5M | — | ||
| Q2 25 | $6.1M | — | ||
| Q1 25 | $4.2M | — | ||
| Q3 24 | $-939.0K | — | ||
| Q2 24 | $-2.6M | — | ||
| Q1 24 | $-1.5M | — | ||
| Q4 23 | $-8.3M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q4 25 | — | -31.7% | ||
| Q3 25 | 7.3% | — | ||
| Q2 25 | 9.2% | — | ||
| Q1 25 | 10.8% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 0.5% | — | ||
| Q4 23 | 2.6% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q3 24 | -0.7% | — | ||
| Q2 24 | -1.6% | — | ||
| Q1 24 | -1.1% | — | ||
| Q4 23 | -5.6% | — |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | $0.08 | — | ||
| Q2 25 | $0.16 | — | ||
| Q1 25 | $0.20 | — | ||
| Q3 24 | $-0.05 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.25 | — | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $59.3M | $197.9M |
| Total DebtLower is stronger | $67.5M | — |
| Stockholders' EquityBook value | $21.0M | $456.1M |
| Total Assets | $125.3M | $638.1M |
| Debt / EquityLower = less leverage | 3.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | $59.3M | — | ||
| Q2 25 | $48.0M | — | ||
| Q1 25 | $35.0M | — | ||
| Q3 24 | $32.2M | — | ||
| Q2 24 | $43.9M | — | ||
| Q1 24 | $42.2M | — | ||
| Q4 23 | $29.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | $67.5M | — | ||
| Q2 25 | $66.5M | — | ||
| Q1 25 | $56.2M | — | ||
| Q3 24 | $44.5M | — | ||
| Q2 24 | $41.2M | — | ||
| Q1 24 | $37.6M | — | ||
| Q4 23 | $22.5M | — |
| Q4 25 | — | $456.1M | ||
| Q3 25 | $21.0M | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $-4.6M | — | ||
| Q3 24 | $-7.9M | — | ||
| Q2 24 | $4.4M | — | ||
| Q1 24 | $5.0M | — | ||
| Q4 23 | — | — |
| Q4 25 | — | $638.1M | ||
| Q3 25 | $125.3M | — | ||
| Q2 25 | $109.1M | — | ||
| Q1 25 | $89.7M | — | ||
| Q3 24 | $87.4M | — | ||
| Q2 24 | $97.5M | — | ||
| Q1 24 | $90.1M | — | ||
| Q4 23 | $74.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.21× | — | ||
| Q2 25 | 14.18× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 9.27× | — | ||
| Q1 24 | 7.54× | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.6M | $-24.8M |
| Free Cash FlowOCF − Capex | $2.5M | $-34.8M |
| FCF MarginFCF / Revenue | 1.6% | -33.5% |
| Capex IntensityCapex / Revenue | 2.5% | 9.6% |
| Cash ConversionOCF / Net Profit | 1.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-24.8M | ||
| Q3 25 | $6.6M | — | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | $16.3M | — | ||
| Q3 24 | $5.8M | — | ||
| Q2 24 | $10.1M | — | ||
| Q1 24 | $1.3M | — | ||
| Q4 23 | $7.5M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $15.9M | — | ||
| Q3 24 | $-1.0M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $789.0K | — | ||
| Q4 23 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 5.7% | — | ||
| Q1 25 | 9.7% | — | ||
| Q3 24 | -0.8% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 0.6% | — | ||
| Q4 23 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q3 24 | 5.0% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.4% | — | ||
| Q4 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.67× | — | ||
| Q1 25 | 3.88× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BTM
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
